Losartan

證據等級: L5

預測適應症: 8 個

LOSARTAN: From Hypertension to Malignant Hypertensive Renal Disease

One-Sentence Summary

Losartan is an angiotensin II receptor blocker (ARB) whose established use is in hypertension and RAAS-mediated cardiovascular/renal protection. The TxGNN model predicts it may also be effective for malignant hypertensive renal disease, but this direction is currently supported by only 1 preclinical (animal-model) publication and no registered clinical trials.

Quick Overview

Item	Content
Original Indication	Hypertension (ARB class); no TFDA-approved indication text is available — this evidence pack shows the drug as 未上市 (not marketed) in Taiwan, with 0 licenses on file
Predicted New Indication	Malignant hypertensive renal disease
TxGNN Prediction Score	99.73%
Evidence Level	L4
US Market Status	未上市 (Not marketed)
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data for this drug is currently unavailable in the evidence pack (flagged as a High-severity data gap). Based on known pharmacology, losartan is an angiotensin II type 1 (AT1) receptor antagonist within the ARB class; its efficacy in hypertension is well established, and mechanistically it may extend to hypertension-driven renal injury.

Malignant hypertensive renal disease shares the same RAAS/AT1 pathophysiology that losartan is designed to block. The one supporting publication (an animal-model study) directly demonstrates that angiotensin II drives NF-κB signaling in malignant hypertensive nephrosclerosis — a mechanistic link consistent with losartan’s known pharmacology, since AT1 blockade would be expected to attenuate this angiotensin II/NF-κB axis.

However, this rationale rests entirely on a preclinical rat model. There is no human clinical data (trial or case-level) specifically evaluating losartan in malignant hypertensive renal disease, so the mechanistic plausibility has not yet been translated into clinical evidence.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
30809002	2019	Preclinical/Mechanistic (animal model)	Hypertension Research	In a rat model of essential hypertension, angiotensin II and NF-κB signaling were shown to drive renal injury; uninephrectomy plus salt overload unmasked latent renal dysfunction, supporting a pathogenic angiotensin II–NF-κB axis in malignant hypertensive nephrosclerosis.

Safety Considerations

Please refer to the package insert for safety information.

(Note: TFDA warnings/contraindications data is a Blocking-severity gap in this evidence pack — see Conclusion below.)

Conclusion and Next Steps

Decision: Hold

Rationale: The predicted indication is currently supported by only a single preclinical (animal-model) publication with no registered clinical trials — evidence level L4, insufficient to justify clinical evaluation. In addition, TFDA label warnings/contraindications data is a Blocking-severity gap, which by itself prevents even a basic (S1) safety assessment.

To proceed, the following is needed:

TFDA package insert (warnings, contraindications) — Blocking gap (DG001), required before any S1 safety review
Drug mechanism-of-action (MOA) detail from DrugBank — High-severity gap (DG002)
Human-level evidence (case series, observational study, or clinical trial) evaluating losartan specifically in malignant hypertensive renal disease
Confirmation of Taiwan market/regulatory status, since this drug currently shows 0 TFDA licenses on file
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.